Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V. Núñez M, et al. Among authors: marino a. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. doi: 10.1097/QAI.0b013e318061b5d9. J Acquir Immune Defic Syndr. 2007. PMID: 17468669 Clinical Trial.
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J; NODy Study Group. Podzamczer D, et al. Among authors: marino a. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):390-6. doi: 10.1097/QAI.0b013e318198a0cc. J Acquir Immune Defic Syndr. 2009. PMID: 19214120 Clinical Trial.
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Echeverría P, Negredo E, Carosi G, Gálvez J, Gómez JL, Ocampo A, Portilla J, Prieto A, López JC, Rubio R, Mariño A, Pedrol E, Viladés C, del Arco A, Moreno A, Bravo I, López-Blazquez R, Pérez-Alvarez N, Clotet B. Echeverría P, et al. Among authors: marino a. Antiviral Res. 2010 Feb;85(2):403-8. doi: 10.1016/j.antiviral.2009.11.008. Epub 2009 Nov 24. Antiviral Res. 2010. PMID: 19941906 Clinical Trial.
Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Rubio R, Serrano O, Carmena J, Asensi V, Echevarría S, Flores J, Ribera E, Zarraga M, Ocampo A, de la Fuente B, Sepúlveda MA, Mariño AI, Minguez C, Vicent R, Cartón JA, Moyano B, Esteban H, Mahillo B, Serrano L, González-García J; GESIDA 44/04 SIMPATAZ Study Group. Rubio R, et al. Among authors: marino ai. HIV Med. 2010 Oct 1;11(9):545-53. doi: 10.1111/j.1468-1293.2010.00827.x. Epub 2010 Mar 19. HIV Med. 2010. PMID: 20345884 Free article.
Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study.
Antela A, Ocampo A, Gómez R, López MJ, Mariño A, Losada E, Rodríguez R, Fernández R, Corredoira JC, Naval G, Rodríguez A, Miralles C, Prieto A, Gevihga Galician HIV Study Group. Antela A, et al. Among authors: marino a. HIV Clin Trials. 2010 Jan-Feb;11(1):11-7. doi: 10.1310/hct1101-11. HIV Clin Trials. 2010. PMID: 20400407
Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.
Pérez-Molina JA, Suárez-Lozano I, Del Arco A, Teira R, Bachiller P, Pedrol E, Martínez-Alfaro E, Domingo P, Mariño A, Ribera E, Antela A, de Otero J, Navarro V, González-García J; Gesida 5808 Study Group. Pérez-Molina JA, et al. Among authors: marino a. HIV Clin Trials. 2011 Jan-Feb;12(1):1-8. doi: 10.1310/hct1201-1. HIV Clin Trials. 2011. PMID: 21388936
Clinical utility of maraviroc.
Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA. Parra J, et al. Among authors: marino a. Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000. Clin Drug Investig. 2011. PMID: 21595497 Review.
1,472 results